Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases – Seeking Alpha
|
Rounds Report: Aimmune Is Gaining Momentum While Editas Experiences Significant Insider Purchases
Seeking Alpha Interestingly, the company employs the gene-editing system coined CRISPR, which is highly prudent. It’s a protein-RNA complex composed of either the protein Cas9 – the case for Crispr Therapeutics (NASDAQ:CRSP) – or Cpf1, each of which binds to a … |
PLoS Blogs (blog) |
A new standard for synthetic biology: Minimum Information Standard for Engineered Organism Experiments (MIEO)
PLoS Blogs (blog) Synthetic biology will realize its potential as an engineering discipline when we can reproduce, exchange, compare, and build upon each other’s work. We have to be able to talk to do that. Standards make it so we can talk to each other effectively. |
NBC 7 San Diego |
Investigating Claims Made By Local Stem Cell Clinic
NBC 7 San Diego The meeting room in the Carlsbad Holiday Inn was filling quickly with men and women, mostly in their 50’s, 60’s, and 70’s, in search of relief from their bad knees and chronic back pain. They were there to attend a free seminar, enticed by TV and … |
KABC-TV |
New advances in ‘PRP’ and stem cell therapy help ease pain of aching joints
KABC-TV Sampson, who’s been doing PRP injections for 12 years, finds that adding a patient’s own stem cells can be very effective. “The cells will travel directly inside the bone to the cartilage surface to potentially regenerate the cartilage and retreat the … |
Proactive Investors Australia |
Cynata Therapeutics treats final patient in stem cell clinical trial
Proactive Investors Australia Cynata’s vice president of product development Dr Kilian Kelly said: “Treating the final patient in the phase I trial of our novel CYP-001 stem cell therapy in GvHD represents a significant milestone and great achievement for Cynata. “In an analysis of … |